GSTM1 and inflammatory bowel disease: A recently reported RCT, the PHOSPHARE-IBD study, had similar efficacy findings in that when same doses of FDI and FCM were administered in a randomized trial to patients with IBD and IDA, the Hb increase was similar throughout the 70-day trial (Hb increase on day 70 with FDI: 24.9 g/L, 95% CI: 21.1-28.8; Hb increase with FCM: 25.2 g/L, 95% CI: 21.3-29.1) [28].